EMEA-003281-PIP01-22 - paediatric investigation plan

Lacutamab

Key facts

• Active Substance:
  Lacutamab
• Therapeutic area:
  Oncology
• Decision number:
  P/0483/2022
• PIP number:
  EMEA-003281-PIP01-22
• Pharmaceutical form(s):
  Solution for injection/infusion
• Condition(s) / indication(s):
  Treatment of Cutaneous T-Cell Lymphoma
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Innate Pharma SA

  E-mail: [e-mail]

  Tel. [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  02/12/2022

Decision

P/0483/2022: EMA decision of 2 December 2022 on the granting of a product specific waiver for lacutamab (EMEA-003281-PIP01-22)

AdoptedReference Number: EMA/871506/2022